(12) United States Patent (10) Patent No.: US 8,048,918 B2 Ward Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) United States Patent (10) Patent No.: US 8,048,918 B2 Ward Et Al USOO8048918B2 (12) United States Patent (10) Patent No.: US 8,048,918 B2 Ward et al. (45) Date of Patent: Nov. 1, 2011 (54) TREATMENT OF HYPERPROLIFERATIVE FOREIGN PATENT DOCUMENTS DISEASES EP 0284.879 A2 10, 1988 EP O610511 8, 1994 GB 2023001. A * 12, 1979 (75) Inventors: Simon Ward, Sheffield (GB); Claes WO WO 97.15298 5, 1999 Bavik, Sheffield (GB); Michael Cork, WO WOO1/30383 5, 2001 Sheffield (GB); Rachid Tazi-Aahnini, WO WO O2/OO2O74 1, 2002 Sheffield (GB) WO WO O2/O72084 9, 2002 (73) Assignee: Vampex Limited, Manchester (GB) OTHER PUBLICATIONS NapoliJL. “Retinol Metabolism in LLC-PK1 Cells. Characterization (*) Notice: Subject to any disclaimer, the term of this of Retinoic Acid Synthesis by an Established Mammalian Cell Line.” patent is extended or adjusted under 35 Journal of Biological Chemistry, 1986:261 (29): 13592-13597.* “Glucocorticoid”. Stedman's Medical Dictionary (Twenty-Second U.S.C. 154(b) by 385 days. Edition). The Williams and Wilkins Company, 1972. p. 527.* Ghosh et al. “Mechanism of Inhibition of 3alpha,20beta (21) Appl. No.: 10/085,239 hydroxysteroid Dehydrogenase by a Licorice-Derived Steroidal Inhibitor”. Structure, Oct. 15, 1994; 2(10):973-980.* (22) Filed: Feb. 27, 2002 Kelloff et al. “Chemopreventive Drug Development: Perspectives and Progress”. Cancer Epidemiology, Biomarkers and Prevention. 3. (65) Prior Publication Data 1994:85-98.* Bavik, Claes et al., “Retinol-Binding Protein Mediates Uptake of US 2003/O1197.15A1 Jun. 26, 2003 Retinol to Cultured Human Keratinocytes'. Exp. Cell Res., vol. 216, pp. 358-62 (1996). Melhus, Hakan et al., “Epitope Mapping of a Monoclonal Antibody Related U.S. Application Data that Blocks the Binding of Retinol-Binding Protein to its Receptor'. (63) Continuation-in-part of application No. Biochem. Biophys. Res. Comm., vol. 210, pp. 105-112 (1995). Connor, M.J. "Modulation of Tumor Promotion in Mouse Skin by the PCT/GB01/03694, filed on Aug. 17, 2001. Food Additive Citral (3,7-dimethyl-2,6-octadienal)', Cancer Lett. vol. 56, pp. 25-28 (1991). (30) Foreign Application Priority Data Estrov, Zeev et al., “Neoplasia: Phenylarsine Oxide Blocks Interleukin-1 (B-Induced Activation of the Nuclear Transcription Fac Aug. 17, 2000 (GB) ................................... OO2O351.3 tor NF-kB, Inhibits Proliferation and Induces Apoptosis of Acute Myelogenous Leukemia Cells'. Blood, pp. 2844-2853 (1999). (51) Int. Cl. AOIN37/02 (2006.01) * cited by examiner AOIN37/10 (2006.01) A6 IK3I/22 (2006.01) Primary Examiner — Leslie A Royds Draper A6 IK3I/9 (2006.01) (74) Attorney, Agent, or Firm — Mintz Levin Cohn Ferris (52) U.S. Cl. ........................................ 514/546; 514/569 Glovsky and Popeo, P.C. (58) Field of Classification Search .................. 514/476, (57) ABSTRACT 514/.406, 504, 703 We describe methods and compositions for treating a patient See application file for complete search history. Suffering from a hyperproliferative disorder or photoageing. (56) References Cited Our methods involve blocking the activity of a retinol binding protein receptor (RBPr) in cells of the patient, and/or admin U.S. PATENT DOCUMENTS istering to the patient an antagonist of a retinol binding pro tein receptor (RBPr) and/or lowering the endogenous level of 4,870,101 A * 9/1989 Ku et al. ....................... 514,476 retinoic acid (RA) in cells of said patient. 5.438,073. A * 8/1995 Saurat et al. 514,452 5,858,750 A * 1/1999 Bandman et al. ............. 435/190 5,917,082 A * 6/1999 Vuligonda et al. ............ 560/100 8 Claims, 11 Drawing Sheets U.S. Patent Nov. 1, 2011 Sheet 1 of 11 US 8,048,918 B2 Figure 1 Cell-death e 9. Therapeutic • Therapeutic target area for target area for 3 5 proposed current therapy 5 therapy 5. 2 Switch-point s C9 5 92 S l Vitamin A Status U.S. Patent Nov. 1, 2011 Sheet 2 of 11 US 8,048,918 B2 Figure 2 Figure 3 RBP normal skin RBPrpsoriatic skin U.S. Patent Nov. 1, 2011 Sheet 3 of 11 US 8,048,918 B2 Figure 4 Proliferation experiment - Anti RBP receptor antibody 25OOO 20000 15OOO 10000 5000 KGM KGM KGM KGM KGM Ca2+ Ca2+ Ca2+ Ca2+ RBP RBP RBP P142 Control IgM U.S. Patent Nov. 1, 2011 Sheet 4 of 11 US 8,048,918 B2 Figure 5 KGM KGM KGM Ca2+ Ca2+ Ca2+ P42 RBP U.S. Patent Nov. 1, 2011 Sheet 5 of 11 US 8,048,918 B2 Figure 6 KGM KGM KGM KGM Ca2+ Ca2+ Ca2+ Ca2+ RBP RBP RBP Peptide 589 Peptide 592 U.S. Patent Nov. 1, 2011 Sheet 6 of 11 US 8,048,918 B2 Figure 7 CoS-1 24 Hours Post Treatment DMEM MEM - P142 DDMEM + Control fg a DMEM - 592 EDMEM + 589 w EDMEM + Control Peptide COS-1 48 Hours Post Treatment DMEM DMEM - P142 L. DMEM + Control ig DMEM + 592 is DMEM - 589 DMEM + Control Peptide U.S. Patent Nov. 1, 2011 Sheet 7 of 11 US 8,048,918 B2 Figure 8 CoS-7 24 Hours Post Treatment DMEM DMEM + P142 TDMEM + Controllg 2. DMEM - 592 DMEM - 589 DMEM + Control Peptide CoS-748 Hours Post Treatment 14OOOO DMEM 120000 . OMEM - P142 1OOOOO 8OOOO DDMEM + Controllg 6OOOO DMEM + 592 40000 20000 E. DMEM + 589 O O OMEM - Conto Peptide U.S. Patent Nov. 1, 2011 Sheet 8 of 11 US 8,048,918 B2 Figure 9 Fibroblast 24 Hours Post Treatment FBGM FBGM + P142 DFBGM+ Control ig a FBGM + 592 a FBGM+589 | E FBGM + Control Peptide Fibroblast after 4 Days of Treatment FBGM FBGM + P142 FBGM + 592 FBGM - 589 | E.E FBGM + Control Peptide U.S. Patent Nov. 1, 2011 Sheet 9 of 11 US 8,048,918 B2 Figure 10 Proliferation Experiment-RA Synthesis inhibitors 25OOO 2OOOO 15OOO 1OOOO 5OOO O KGM KGM KGM KGM KGM KGM KGM Cell Ca2+ ROL DisulfiROL CitraROL. R. RA Numbers a. Carben. U.S. Patent Nov. 1, 2011 Sheet 10 of 11 US 8,048,918 B2 Figure 11 KGM KGM KGM KGM Ca2+ Ca2+ Ca2+ Ca2+ ROL ROL ROL Disulfiram Citral U.S. Patent Nov. 1, 2011 Sheet 11 of 11 US 8,048,918 B2 Figure 12 US 8,048,918 B2 1. 2 TREATMENT OF HYPERPROLIFERATIVE inoids on hyperproliferative cells, i.e., reduced proliferation DISEASES and/or enhanced differentiation, as well as reversing the effects of photoageing, without exposing cells of a diseased or CROSS REFERENCE TO RELATED affected patient to pharmacological doses of retinoids. Such APPLICATIONS pharmacological doses are described below. This application is a continuation-in-part of international We have found that these physiological effects of retinoid application PCT/GB01/03694, filed Aug. 17, 2001 and therapy are achieved by reducing the endogenous level of claims priority from Great Britain Application No. retinoic acid in hyperproliferative cells or cells suffering from 0020351.3, filed Aug. 17, 2000. The above-mentioned appli photoageing. Reduction of the endogenous level of retinoic cations, as well as all documents cited herein and documents 10 acid in cells may beachieved in various ways, for example, by referenced or cited in documents cited herein, are hereby blocking the activity of a retinol binding protein receptor incorporated herein by reference. (RBPr) which transports retinol into the cell. Such blocking may be done by administering an antagonist of retinol bind FIELD 15 ing protein receptor to the patient. The antagonist as This invention relates to the treatment of diseases associ described above preferably comprises an agent which is ated with cellular hyperproliferation in a patient, including capable of inhibiting the interaction of retinol binding protein psoriasis and cancer. The invention also relates to the treat receptor with retinol binding protein. The antagonist may ment or alleviation of symptoms associated with photoage inhibit the interaction by binding to one or other, or both, of 1ng. the retinol binding protein receptor and the retinol binding protein. Furthermore, inhibition of any of the enzymatically BACKGROUND catalysed reactions in a pathway responsible for retinoic acid biosynthesis may also be used to reduce retinoic acid levels in A number of diseases are associated with hyperprolifera the cell. tion of cells, including psoriasis, the ichthyoses, cancer and 25 cutaneous viral infections. Psoriasis is a chronic inflamma According to a first aspect of the invention, we provide a tory disease characterised by hyperproliferation and impaired method of treating a patient Suffering from a hyperprolifera differentiation of keratinocytes. Currently, the symptoms of tive disorder or photoageing, which method comprises low psoriasis are treated in a number of ways, including topical ering the endogenous level or activity of retinoic acid (RA) in administration of retinoids to the patient. Other diseases such a cell of the patient. Other aspects of the invention, and as acne Vulgaris and photoageing also respond to retinoid 30 preferred embodiments, are set out in the independent and therapy and are believed to involve additional retinoid-medi dependent claims as well as in the description. ated mechanisms. Retinoids have also been used for both treatment and pre BRIEF DESCRIPTION OF THE DRAWINGS vention of the development of cancers (e.g. treatment of acute promyelocytic leukaemia and prevention of the development 35 FIG. 1 is a diagram representing the relationship between of cutaneous malignancies in renal transplant patients). current forms of retinoid therapy and an embodiment of a Current retinoid therapy is based upon the effect of car method according to our invention. The figure shows cell boxylic acid derivatives of vitamin A (in particular, retinoic response, as measured by its resting State of proliferation, acid, the endogenously active compound) which are able to differentiation or death (cytotoxicity leading to necrosis), to transcriptionally regulate target genes. Exposure to retinoic 40 increasing concentrations of retinoic acid (endogenous vita acid and retinoids results in proliferating cells withdrawing min A signal derived from retinol in the blood and delivered from the cell cycle and differentiating in response to retinoic to the cell by retinol binding protein-retinol binding protein acid-induced transcription of a possible excess of 300 target receptor interaction).
Recommended publications
  • Supplementary Materials
    1 Supplementary Materials: Supplemental Figure 1. Gene expression profiles of kidneys in the Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice. (A) A heat map of microarray data show the genes that significantly changed up to 2 fold compared between Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice (N=4 mice per group; p<0.05). Data show in log2 (sample/wild-type). 2 Supplemental Figure 2. Sting signaling is essential for immuno-phenotypes of the Fcgr2b-/-lupus mice. (A-C) Flow cytometry analysis of splenocytes isolated from wild-type, Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice at the age of 6-7 months (N= 13-14 per group). Data shown in the percentage of (A) CD4+ ICOS+ cells, (B) B220+ I-Ab+ cells and (C) CD138+ cells. Data show as mean ± SEM (*p < 0.05, **p<0.01 and ***p<0.001). 3 Supplemental Figure 3. Phenotypes of Sting activated dendritic cells. (A) Representative of western blot analysis from immunoprecipitation with Sting of Fcgr2b-/- mice (N= 4). The band was shown in STING protein of activated BMDC with DMXAA at 0, 3 and 6 hr. and phosphorylation of STING at Ser357. (B) Mass spectra of phosphorylation of STING at Ser357 of activated BMDC from Fcgr2b-/- mice after stimulated with DMXAA for 3 hour and followed by immunoprecipitation with STING. (C) Sting-activated BMDC were co-cultured with LYN inhibitor PP2 and analyzed by flow cytometry, which showed the mean fluorescence intensity (MFI) of IAb expressing DC (N = 3 mice per group). 4 Supplemental Table 1. Lists of up and down of regulated proteins Accession No.
    [Show full text]
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS
    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
    [Show full text]
  • Serum Albumin OS=Homo Sapiens
    Protein Name Cluster of Glial fibrillary acidic protein OS=Homo sapiens GN=GFAP PE=1 SV=1 (P14136) Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 Cluster of Isoform 3 of Plectin OS=Homo sapiens GN=PLEC (Q15149-3) Cluster of Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 (P68871) Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 Cluster of Tubulin beta-3 chain OS=Homo sapiens GN=TUBB3 PE=1 SV=2 (Q13509) Cluster of Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 (P60709) Cluster of Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 (P68363) Cluster of Isoform 2 of Spectrin alpha chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTAN1 (Q13813-2) Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 Cluster of Spectrin beta chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTBN1 PE=1 SV=2 (Q01082) Cluster of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM PE=1 SV=4 (P14618) Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 Cytoplasmic dynein 1 heavy chain 1 OS=Homo sapiens GN=DYNC1H1 PE=1 SV=5 Cluster of ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide OS=Homo sapiens GN=ATP1A2 PE=3 SV=1 (B1AKY9) Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 Dihydropyrimidinase-related protein 2 OS=Homo sapiens GN=DPYSL2 PE=1 SV=1 Cluster of Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 (P12814) 60 kDa heat shock protein, mitochondrial OS=Homo
    [Show full text]
  • Supplementary Materials
    Supplementary Materials COMPARATIVE ANALYSIS OF THE TRANSCRIPTOME, PROTEOME AND miRNA PROFILE OF KUPFFER CELLS AND MONOCYTES Andrey Elchaninov1,3*, Anastasiya Lokhonina1,3, Maria Nikitina2, Polina Vishnyakova1,3, Andrey Makarov1, Irina Arutyunyan1, Anastasiya Poltavets1, Evgeniya Kananykhina2, Sergey Kovalchuk4, Evgeny Karpulevich5,6, Galina Bolshakova2, Gennady Sukhikh1, Timur Fatkhudinov2,3 1 Laboratory of Regenerative Medicine, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov of Ministry of Healthcare of Russian Federation, Moscow, Russia 2 Laboratory of Growth and Development, Scientific Research Institute of Human Morphology, Moscow, Russia 3 Histology Department, Medical Institute, Peoples' Friendship University of Russia, Moscow, Russia 4 Laboratory of Bioinformatic methods for Combinatorial Chemistry and Biology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia 5 Information Systems Department, Ivannikov Institute for System Programming of the Russian Academy of Sciences, Moscow, Russia 6 Genome Engineering Laboratory, Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region, Russia Figure S1. Flow cytometry analysis of unsorted blood sample. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S2. Flow cytometry analysis of unsorted liver stromal cells. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S3. MiRNAs expression analysis in monocytes and Kupffer cells. Full-length of heatmaps are presented.
    [Show full text]
  • Chemistry of a Dehydrogenase and Di-Heme Enzyme Related to Tryptophan Oxidation
    Georgia State University ScholarWorks @ Georgia State University Chemistry Dissertations Department of Chemistry 8-10-2021 Chemistry of a Dehydrogenase and Di-heme Enzyme Related to Tryptophan Oxidation Christopher Ian Davis Georgia State University Follow this and additional works at: https://scholarworks.gsu.edu/chemistry_diss Recommended Citation Davis, Christopher Ian, "Chemistry of a Dehydrogenase and Di-heme Enzyme Related to Tryptophan Oxidation." Dissertation, Georgia State University, 2021. https://scholarworks.gsu.edu/chemistry_diss/201 This Dissertation is brought to you for free and open access by the Department of Chemistry at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Chemistry Dissertations by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact [email protected]. CHEMISTRY OF A DEHYDROGENASE AND DI-HEME ENZYME RELATED TO TRYPTOPHAN OXIDATION by CHRISTOPHER IAN DAVIS Under the Direction of Aimin Liu PhD ABSTRACT Tryptophan is an essential amino acid that is used as a building block to construct proteins, the biosynthetic precursor for several essential molecules, and is modified to serve as a cofactor in some enzymes. This dissertation focuses on two enzymes involved in tryptophan oxidation, AMSDH and MauG. AMSDH is a dehydrogenase in the kynurenine pathway, which is the main metabolic route for tryptophan catabolism. In addition to breaking down tryptophan, the kynurenine pathway is also involved in regulating the innate immune response, NAD biosynthesis, and some neurodegenerative. As such, enzymes of the kynurenine pathway are of fundamental interest for study. This work leveraged a bacterial homologue of human AMSDH to solve its crystal structure in various forms, including several catalytic intermediates.
    [Show full text]
  • Key Enzymes of the Retinoid (Visual) Cycle in Vertebrate Retina☆
    Biochimica et Biophysica Acta 1821 (2012) 137–151 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbalip Review Key enzymes of the retinoid (visual) cycle in vertebrate retina☆ Philip D. Kiser a,1, Marcin Golczak a,1, Akiko Maeda a,b,⁎, Krzysztof Palczewski a,⁎⁎ a Department of Pharmacology, Case Western Reserve University, Cleveland, OH, 44106-4965, USA b Department of Ophthalmology and Vision Sciences, Case Western Reserve University, Cleveland, OH, 44106-4965, USA article info abstract Article history: A major goal in vision research over the past few decades has been to understand the molecular details of Received 19 January 2011 retinoid processing within the retinoid (visual) cycle. This includes the consequences of side reactions that Received in revised form 8 March 2011 result from delayed all-trans-retinal clearance and condensation with phospholipids that characterize a Accepted 22 March 2011 variety of serious retinal diseases. Knowledge of the basic retinoid biochemistry involved in these diseases is Available online 5 April 2011 essential for development of effective therapeutics. Photoisomerization of the 11-cis-retinal chromophore of rhodopsin triggers a complex set of metabolic transformations collectively termed phototransduction that Keywords: RPE65 ultimately lead to light perception. Continuity of vision depends on continuous conversion of all-trans-retinal Retinol dehydrogenase back to the 11-cis-retinal isomer. This process takes place in a series of reactions known as the retinoid cycle, Visual cycle which occur in photoreceptor and RPE cells. All-trans-retinal, the initial substrate of this cycle, is a chemically Retinoid cycle reactive aldehyde that can form toxic conjugates with proteins and lipids.
    [Show full text]
  • Protein Network Analyses of Pulmonary Endothelial Cells In
    www.nature.com/scientificreports OPEN Protein network analyses of pulmonary endothelial cells in chronic thromboembolic pulmonary hypertension Sarath Babu Nukala1,8,9*, Olga Tura‑Ceide3,4,5,9, Giancarlo Aldini1, Valérie F. E. D. Smolders2,3, Isabel Blanco3,4, Victor I. Peinado3,4, Manuel Castell6, Joan Albert Barber3,4, Alessandra Altomare1, Giovanna Baron1, Marina Carini1, Marta Cascante2,7,9 & Alfonsina D’Amato1,9* Chronic thromboembolic pulmonary hypertension (CTEPH) is a vascular disease characterized by the presence of organized thromboembolic material in pulmonary arteries leading to increased vascular resistance, heart failure and death. Dysfunction of endothelial cells is involved in CTEPH. The present study describes for the frst time the molecular processes underlying endothelial dysfunction in the development of the CTEPH. The advanced analytical approach and the protein network analyses of patient derived CTEPH endothelial cells allowed the quantitation of 3258 proteins. The 673 diferentially regulated proteins were associated with functional and disease protein network modules. The protein network analyses resulted in the characterization of dysregulated pathways associated with endothelial dysfunction, such as mitochondrial dysfunction, oxidative phosphorylation, sirtuin signaling, infammatory response, oxidative stress and fatty acid metabolism related pathways. In addition, the quantifcation of advanced oxidation protein products, total protein carbonyl content, and intracellular reactive oxygen species resulted increased
    [Show full text]
  • Characterization of Cd36 03230P, a Putative Vanillin Dehydrogenase from Candida Dubliniensis† Cite This: RSC Adv.,2016,6, 99774 Suprama Datta,Ab Uday S
    RSC Advances View Article Online COMMUNICATION View Journal | View Issue Characterization of Cd36_03230p, a putative vanillin dehydrogenase from Candida dubliniensis† Cite this: RSC Adv.,2016,6, 99774 Suprama Datta,ab Uday S. Annapureb and David J. Timson*ac Received 5th September 2016 Accepted 10th October 2016 DOI: 10.1039/c6ra22209a www.rsc.org/advances A coding sequence (CD36-03230) from the yeast Candida dubliniensis derived phenylpropanoids (such as vanillin, vanillate, caffeate, p- had been previously annotated as a vanillin dehydrogenase (VDH). The coumarate, cinnamate and benzaldehyde). These aromatic alde- corresponding protein (CD36-03230p) was recombinantly expressed hydes, especially vanillin, are abundant as avour and aromas in in Escherichia coli and analysed. The protein is most likely a tetramer in food and cosmetic industries. It is important to elucidate the Creative Commons Attribution 3.0 Unported Licence. solution as judged by crosslinking and gel filtration experiments. structural and functional characteristics of these enzymes given CD36-03230p is an active aldehyde dehydrogenase favouring cyclic their potential role in food chemistry and biotechnology. This and aromatic substrates. Positive cooperativity and substrate inhibition group of enzymes has been characterized in a number of eubac- were observed with some substrates. The redox cofactor NADP+ and terial species, including Pseudomonas uorescens,6 Pseudomonas substrates affected the thermal stability of the protein. Interestingly, putida KT2440,13 Corynebacterium
    [Show full text]
  • Index of Recommended Enzyme Names
    Index of Recommended Enzyme Names EC-No. Recommended Name Page 1.2.1.10 acetaldehyde dehydrogenase (acetylating) 115 1.2.1.38 N-acetyl-y-glutamyl-phosphate reductase 289 1.2.1.3 aldehyde dehydrogenase (NAD+) 32 1.2.1.4 aldehyde dehydrogenase (NADP+) 63 1.2.99.3 aldehyde dehydrogenase (pyrroloquinoline-quinone) 578 1.2.1.5 aldehyde dehydrogenase [NAD(P)+] 72 1.2.3.1 aldehyde oxidase 425 1.2.1.31 L-aminoadipate-semialdehyde dehydrogenase 262 1.2.1.19 aminobutyraldehyde dehydrogenase 195 1.2.1.32 aminomuconate-semialdehyde dehydrogenase 271 1.2.1.29 aryl-aldehyde dehydrogenase 255 1.2.1.30 aryl-aldehyde dehydrogenase (NADP+) 257 1.2.3.9 aryl-aldehyde oxidase 471 1.2.1.11 aspartate-semialdehyde dehydrogenase 125 1.2.1.6 benzaldehyde dehydrogenase (deleted) 88 1.2.1.28 benzaldehyde dehydrogenase (NAD+) 246 1.2.1.7 benzaldehyde dehydrogenase (NADP+) 89 1.2.1.8 betaine-aldehyde dehydrogenase 94 1.2.1.57 butanal dehydrogenase 372 1.2.99.2 carbon-monoxide dehydrogenase 564 1.2.3.10 carbon-monoxide oxidase 475 1.2.2.4 carbon-monoxide oxygenase (cytochrome b-561) 422 1.2.1.45 4-carboxy-2-hydroxymuconate-6-semialdehyde dehydrogenase .... 323 1.2.99.6 carboxylate reductase 598 1.2.1.60 5-carboxymethyl-2-hydroxymuconic-semialdehyde dehydrogenase . 383 1.2.1.44 cinnamoyl-CoA reductase 316 1.2.1.68 coniferyl-aldehyde dehydrogenase 405 1.2.1.33 (R)-dehydropantoate dehydrogenase 278 1.2.1.26 2,5-dioxovalerate dehydrogenase 239 1.2.1.69 fluoroacetaldehyde dehydrogenase 408 1.2.1.46 formaldehyde dehydrogenase 328 1.2.1.1 formaldehyde dehydrogenase (glutathione)
    [Show full text]
  • O O2 Enzymes Available from Sigma Enzymes Available from Sigma
    COO 2.7.1.15 Ribokinase OXIDOREDUCTASES CONH2 COO 2.7.1.16 Ribulokinase 1.1.1.1 Alcohol dehydrogenase BLOOD GROUP + O O + O O 1.1.1.3 Homoserine dehydrogenase HYALURONIC ACID DERMATAN ALGINATES O-ANTIGENS STARCH GLYCOGEN CH COO N COO 2.7.1.17 Xylulokinase P GLYCOPROTEINS SUBSTANCES 2 OH N + COO 1.1.1.8 Glycerol-3-phosphate dehydrogenase Ribose -O - P - O - P - O- Adenosine(P) Ribose - O - P - O - P - O -Adenosine NICOTINATE 2.7.1.19 Phosphoribulokinase GANGLIOSIDES PEPTIDO- CH OH CH OH N 1 + COO 1.1.1.9 D-Xylulose reductase 2 2 NH .2.1 2.7.1.24 Dephospho-CoA kinase O CHITIN CHONDROITIN PECTIN INULIN CELLULOSE O O NH O O O O Ribose- P 2.4 N N RP 1.1.1.10 l-Xylulose reductase MUCINS GLYCAN 6.3.5.1 2.7.7.18 2.7.1.25 Adenylylsulfate kinase CH2OH HO Indoleacetate Indoxyl + 1.1.1.14 l-Iditol dehydrogenase L O O O Desamino-NAD Nicotinate- Quinolinate- A 2.7.1.28 Triokinase O O 1.1.1.132 HO (Auxin) NAD(P) 6.3.1.5 2.4.2.19 1.1.1.19 Glucuronate reductase CHOH - 2.4.1.68 CH3 OH OH OH nucleotide 2.7.1.30 Glycerol kinase Y - COO nucleotide 2.7.1.31 Glycerate kinase 1.1.1.21 Aldehyde reductase AcNH CHOH COO 6.3.2.7-10 2.4.1.69 O 1.2.3.7 2.4.2.19 R OPPT OH OH + 1.1.1.22 UDPglucose dehydrogenase 2.4.99.7 HO O OPPU HO 2.7.1.32 Choline kinase S CH2OH 6.3.2.13 OH OPPU CH HO CH2CH(NH3)COO HO CH CH NH HO CH2CH2NHCOCH3 CH O CH CH NHCOCH COO 1.1.1.23 Histidinol dehydrogenase OPC 2.4.1.17 3 2.4.1.29 CH CHO 2 2 2 3 2 2 3 O 2.7.1.33 Pantothenate kinase CH3CH NHAC OH OH OH LACTOSE 2 COO 1.1.1.25 Shikimate dehydrogenase A HO HO OPPG CH OH 2.7.1.34 Pantetheine kinase UDP- TDP-Rhamnose 2 NH NH NH NH N M 2.7.1.36 Mevalonate kinase 1.1.1.27 Lactate dehydrogenase HO COO- GDP- 2.4.1.21 O NH NH 4.1.1.28 2.3.1.5 2.1.1.4 1.1.1.29 Glycerate dehydrogenase C UDP-N-Ac-Muramate Iduronate OH 2.4.1.1 2.4.1.11 HO 5-Hydroxy- 5-Hydroxytryptamine N-Acetyl-serotonin N-Acetyl-5-O-methyl-serotonin Quinolinate 2.7.1.39 Homoserine kinase Mannuronate CH3 etc.
    [Show full text]
  • Supplementary Information
    Supplementary Information Table S1. Identification of amyloid-binding proteins in mouse brain homogenates. No. Protein Name Acc. Number a Mol. Mass Score b Peptides Localization Function 1 Carbamoyl-phosphate synthase [ammonia], mitochondrial CPSM_RAT 164,476 1129 15 M 6 2 Pyruvate kinase isozymes M1/M2 KPYM_RAT 57,781 706 7 C, N 1 3 Betaine—Homocysteine S-methyltransferase 1 BHMT1_RAT 44,948 650 2 C 6 4 Adenylate kinase 2, mitochondrial KAD2_RAT 26,363 540 4 M 1 5 δ-1-Pyrroline-5-carboxylate dehydrogenase, mitochondrial AL4A1_RAT 61,830 538 4 M 6 6 Actin, cytoplasmic 1 ACTB_RAT 41,710 524 3 C 2 # 7 Myosin-4 MYH4_RAT 222,741 396 4 C 2 8 3-Ketoacyl-CoA thiolase, mitochondrial THIM_RAT 41,844 350 1 M 7 9 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial HCDH_RAT 34,426 310 3 M 7 10 Heat shock cognate 71 kDa protein HSP7C_RAT 70,827 305 3 C, N, S, Mel 5 # 11 ATP synthase subunit β, mitochondrial ATPB_RAT 56,318 290 4 M 1 # 12 Calmodulin CALM_RAT 16,827 288 1 C 2 # 13 Fructose-bisphosphate aldolase B ALDOB_RAT 39,593 249 2 C, L, N, ER, CM 1 # 14 α-Enolase ENOA_RAT 47,098 220 2 CM, C, Me 1 # 15 Ornithine carbamoyltransferase, mitochondrial OTC_RAT 39,861 212 5 M 6 16 Myelin basic protein S MBP_RAT 21,489 211 1 CM, Me 5 17 Glutathione S-transferase α-2 GSTA2_RAT 25,543 208 1 C, M, N 5 18 Phosphatidylethanolamine-binding protein 1 PEBP1_RAT 20,788 182 1 C, Me 4 19 Dihydropyrimidinase-related protein 2 DPYL2_RAT 62,239 177 2 C, Me, M 3 # 20 60 kDa Heat shock protein, mitochondrial CH60_RAT 60,917 162 4 M 5 21 Glyceraldehyde-3-phosphate dehydrogenase G3P_RAT 35,787 160 1 C, N 1 # 22 Electron transfer flavoprotein subunit α, mitochondrial ETFA_RAT 34,929 137 3 M 1 23 Fructose-bisphosphate aldolase A ALDOA_RAT 39,327 135 2 Me, M 1 24 ATP synthase subunit α, mitochondrial ATPA_RAT 59,717 131 2 M 1 25 Thioredoxin-dependent peroxide reductase, mitochondrial PRDX3_RAT 28,277 130 1 M 5 26 Elongation factor 1-α 1 EF1A1_RAT 50,082 129 2 N 3 27 Endoplasmin ENPL_RAT 92,713 125 1 ER 5 S2 Table S1.
    [Show full text]
  • UNIVERSITY of CALIFORNIA Los Angeles New Mechanisms for Regeneration of Visual Pigments in the Vertebrate Retina a Dissertation
    UNIVERSITY OF CALIFORNIA Los Angeles New Mechanisms for Regeneration of Visual Pigments in the Vertebrate Retina A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Molecular, Cellular, and Integrative Physiology by Tongzhou Xu 2017 © Copyright by Tongzhou Xu 2017 ABSTRACT OF THE DISSERTATION New Mechanisms for Regeneration of Visual Pigments in the Vertebrate Retina by Tongzhou Xu Doctor of Philosophy in Molecular, Cellular, and Integrative Physiology University of California, Los Angeles, 2017 Professor Gabriel H. Travis, Chair Vision begins when a photon is captured by a visual pigment in a photoreceptor cell. For most vertebrates, the light-sensitive chromophore in the visual pigment is 11-cis- retinaldehyde (11-cis-retinal), which is covalently bound to the protein moiety, opsin, through a Schiff base linkage. The absorption of a photon isomerizes 11-cis-retinal to its all-trans-isomer and activates the visual pigment. In vertebrate ciliary photoreceptors, after a brief activation, the pigment decays to yield apo-opsin and free all-trans-retinal. Light sensitivity restoration in photoreceptor cells occurs following re-isomerization of all-trans-retinal to 11-cis-retinal by enzymatic pathways termed “visual cycles”. At present, two visual cycles have been established: (1) A well understood canonical visual cycle between RPE cells and photoreceptors, with RPE65 as its retinoid isomerase (Isomerase I); (2) A relatively under characterized alternate visual cycle between Müller cells and cones, with an unknown retinoid isomerase (Isomerase II). Recently, we have identified dihydroceramide desaturase-1 (DES1) as a novel retinoid isomerase and a strong candidate for Isomerase II.
    [Show full text]